Prognostic Relevance of Biological Subtype in Breast Cancer
NCT ID: NCT02063906
Last Updated: 2017-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
202 participants
OBSERVATIONAL
2014-02-28
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Alteration After Systemic Treatment in Breast Cancer
NCT02591966
Identification of New Prognostic Markers for Breast Cancer.
NCT03436069
Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer
NCT01514565
Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer
NCT05896865
Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery
NCT03188393
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Breast cancer stage I-III
who received curative surgery for stage I-III breast cancer and had available data on immunohistochemistry profiles including hormone receptor status (HR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung Medical Center from January 2004 to September 2008.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stage I-III breast cancer
* between January 2004 and September 2008
* had available immunohistochemistry profiles.
Exclusion Criteria
* microinvasive carcinoma of breast
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young-Hyuck Im
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Young-Hyuck Im, Pf
Role: PRINCIPAL_INVESTIGATOR
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-02-045
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.